Income statement, balance sheet and cash flow statement for the last 7 fiscal years, taken from the XBRL data Celularity Inc files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
14.3
21.3
18
22.8
54.2
26.6
Cost of revenue
16
15
20.1
Gross profit
9.35
11.7
-1.69
6.76
39.2
6.48
Research and development
52.7
88.4
78.4
30.5
17.4
15
Selling, general and administrative
31.3
71.3
66
50.6
58.6
51.3
Selling and marketing
0.76
0.25
0.16
0.04
0.02
0.02
Operating income
-1.68
-152
-109
-25.6
-192
-38.4
-61.3
Interest income
3.75
1.78
Other non-operating income
8.23
-61
8.96
39.8
-4
-19.5
-30.4
Pre-tax income
6.55
-213
-100
14.2
-196
-57.9
-91.7
Income tax
0.67
-4.7
0.02
0.01
0.01
0
Income from continuing operations
-152
-109
-25.6
-192
-38.4
-61.3
Net income
5.88
-208
-100
14.2
-196
-57.9
-91.7
EBITDA
-144
-100
-16.2
-183
-30.4
-54
EPS, basic
1.06
-119.38
-15.73
1.01
-11.02
-2.64
-3.59
EPS, diluted
1.06
-119.38
-15.73
0.95
-11.02
-2.64
-3.59
Shares, basic (weighted)
2.42
1.74
6.35
14
17.8
21.9
25.6
Shares, diluted (weighted)
2.42
1.74
6.35
15
17.8
21.9
25.6
Balance sheet
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
0.92
54.3
37.2
14
0.23
0.74
6.18
Receivables
4.65
Inventory
9.55
9.55
5.31
5.75
5.41
0.57
Other current assets
0.09
0.87
0
7.26
1.7
0.86
0.92
Total current assets
1.01
72.2
59.1
33.5
19.8
20.6
12.3
Property, plant and equipment
90.1
90.6
75.7
67.8
61.6
55.8
Lease right-of-use assets
13.1
11
10.8
10.7
Goodwill
127
123
123
120
7.35
7.35
7.35
Intangible assets
125
123
121
11
9.25
7.76
Other non-current assets
2.89
0.36
0.38
0.34
0.27
0.25
Total assets
292
431
414
401
144
133
107
Accounts payable
0.21
5.39
9.32
5.81
14.1
23.3
26.4
Accrued liabilities
13.5
11.7
9.07
7.58
20.5
32.6
Deferred revenue
4.83
2.2
2.27
2.83
3.53
5.26
Short-term debt
37.6
39.2
Total current liabilities
0.23
26.7
26.2
62.1
67.3
53.7
80.8
Long-term debt
33.8
Lease liabilities
28
26.2
26.5
26.9
Other non-current liabilities
0.35
0.34
0.32
0.29
0.28
0.27
Total liabilities
28.2
412
315
202
103
124
145
Total debt
33.8
Paid-in capital
1.12
32.4
763
844
883
909
953
Retained earnings
3.88
-564
-664
-645
-842
-900
-991
Treasury stock
-0.26
Other comprehensive income
0.01
-0.01
Shareholders' equity
-327
-531
99.4
199
41
8.84
-38.1
Total equity
5
-531
99.4
199
41
8.84
-38.1
Total liabilities and equity
292
431
414
401
144
133
107
Shares outstanding
0.3
1.76
11.8
14.9
19.4
22.5
28.8
Cash flow statement
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
5.88
-208
-100
14.2
-196
-57.9
-91.7
Depreciation and amortization
8.17
8.82
9.44
9.32
7.92
7.3
Stock-based compensation
4.37
40
15.9
0
11.6
10.6
Deferred income tax
-0
-4.72
0
-0
Change in receivables
1.65
-1.91
-3.58
-6.83
-3.97
7.55
Change in inventory
-0.64
-6.42
-16.9
-0.87
6.28
10.2
Change in payables
0.21
0.31
3.01
-2.95
8.5
9.24
3.13
Cash from operations
-1.1
-63.2
-110
-138
-38.7
-6.4
-13.3
Capital expenditures
-27.8
-6.2
-5.24
-1.05
-0.16
Purchases of investments
-288
Cash from investing
-287
-12.8
-5.9
-5.24
-4.05
0.51
Stock issued
0.14
0.64
0.86
0.3
0.06
1.04
Share buybacks
-0.26
Cash from financing
289
102
98.6
120
24.1
6.7
18.6
Net change in cash
0.89
26
-17.4
-23.3
-18.6
0.81
5.4
Free cash flow
-91
-116
-143
-39.7
-6.56
Interest paid
0.15
1.07
0.14
2.5
Income taxes paid
0.65
0.01
0.05
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to March 31, 2026; growth uses fiscal years. Valuation uses the share price of $0.75 on November 11, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
5.3%
Gross profit / revenue.
Operating margin
-321.3%
Operating income / revenue.
EBITDA margin
-288.1%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-374.7%
Pre-tax income / revenue.
Net margin
-374.7%
Net income / revenue.
Operating cash flow margin
-46.5%
Cash from operations / revenue.
Return on assets (ROA)
-71.5%
Net income / average total assets.
R&D / revenue
75.3%
Research and development expense / revenue.
SG&A / revenue
243.4%
Selling, general and administrative expense / revenue.
Stock-based pay / revenue
28.1%
Stock-based compensation (from the cash flow statement) / revenue.
D&A / revenue
33.3%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-51.0%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
13.9%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
13.2%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y
-83.5%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 5y
-7.1%
Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
-530.7%
Book value vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
-19.1%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-35.6%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-24.3%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
16.9%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
19.5%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
71.1%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.09x
Current assets / current liabilities.
Quick ratio
0.07x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.01x
(Cash + short-term investments) / current liabilities.
Days inventory + days sales outstanding - days payables.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$2.35
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.63
Revenue / diluted weighted shares.
Operating cash flow per share
-$0.29
Cash from operations / diluted weighted shares.
Book value per share
-$1.21
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
1.15x
Market cap / revenue.
EV/Sales
1.13x
Enterprise value / revenue.
Earnings yield
-327.0%
Net income / market cap (the inverse of P/E).
What was Celularity Inc's revenue in fiscal 2025?
Celularity Inc reported revenue of $26.6M for fiscal 2025, 51% lower than the year before.
Was Celularity Inc profitable in fiscal 2025?
No. It reported a net loss of $91.7M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.